The latest healthcare forecast report provides an in-depth analysis of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma, offering comprehensive insights into the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma revenue trends, prevalence, and treatment landscape. The report delves into key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging CAR T-Cell Therapy for Non-Hodgkin’s lymphoma therapies. Additionally, we cover the landscape of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma space.
To Know in detail about the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Forecast
Some of the key facts of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Report:
- The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
- In November 2024, Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company developing next-generation CAR T-cell therapies for patients with solid tumors or hematologic cancers, announced that an abstract featuring initial clinical data from the Phase 1-2 study of IMPT-314 in large B-cell lymphoma will be presented by Dr. Sarah M. Larson, Associate Professor, Department of Medicine and Medical Director of the Immune Effector Cell Therapy Program at the David Geffen School of Medicine at UCLA, during the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA, from December 7 to 10, 2024. IMPT-314 is a dual-targeting CD19/CD20 CAR T-cell therapy being developed for patients with aggressive B-cell non-Hodgkin’s lymphoma.
- In May 2024, Verismo Therapeutics obtained FDA IND clearance for SynKIR-310 in relapsed/refractory B-cell NHL.
- In March 2024, Bristol Myers Squibb announced that the US FDA has approved BREYANZI as the first and only CAR T-cell therapy for adults with relapsed/refractory CLL or SLL.
- Key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Companies: Hrain Biotechnology, Lazaros Lekakis, Beijing Immunochina Medical Science, Juno Therapeutics, Gilead Sciences, Novartis, BMS, Allogene Therapeutics, Miltenyi Biomedicine, Autolus Therapeutics, Tessa Therapeutics, and others
- Key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Therapies: Human CD19Targeted T Cells Injection, Mosunetuzumab, IM19 CAR-T Cells, lisocabtagene maraleucel, YESCARTA, KYMRIAH, BREYANZI, Cemacabtagene ansegedleucel, Rapcabtagene autoleucel (YTB323), Zamtocabtagene autoleucel, AUTO4, CD30.CAR-T, and others
- The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage CAR T-Cell Therapy for Non-Hodgkin’s lymphoma pipeline products will significantly revolutionize the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market dynamics.
- According to DelveInsight's estimates, the total number of NHL cases eligible for CAR-T therapy in the 7MM was approximately 125,900 in 2023.
- DLBCL is the most common subtype of non-Hodgkin lymphoma in the EU4 and UK, with around 32,400 cases reported in 2023.
- In 2023, Japan reported around 23,700 incident cases of NHL across selected subtypes.
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Overview
Chimeric Antigen Receptor (CAR) T-cell therapy is an innovative treatment for certain types of Non-Hodgkin’s lymphoma. It involves modifying a patient's own T-cells (a type of immune cell) to express a receptor that targets and kills cancerous B-cells, which are typically present in NHL. These modified T-cells are then infused back into the patient, where they recognize and destroy lymphoma cells. CAR T-cell therapy has shown promising results for patients with relapsed or refractory NHL, particularly for aggressive forms of the disease. It is considered a breakthrough in cancer immunotherapy due to its ability to harness the body's immune system for targeted treatment.
Get a Free sample for the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Forecast, Size Share Analysis Report:
https://www.delveinsight.com/report-store/car-t-cell-therapy-for-non-hodgkins-lymphoma-market
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology Segmentation:
The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Total Prevalence of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma
- Prevalent Cases of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma by severity
- Gender-specific Prevalence of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma
- Diagnosed Cases of Episodic and Chronic CAR T-Cell Therapy for Non-Hodgkin’s lymphoma
Download the report to understand which factors are driving CAR T-Cell Therapy for Non-Hodgkin’s lymphoma epidemiology trends @ CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology Forecast
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market or expected to get launched during the study period. The analysis covers CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Therapies and Key Companies
- Human CD19Targeted T Cells Injection: Hrain Biotechnology
- Mosunetuzumab: Lazaros Lekakis
- IM19 CAR-T Cells: Beijing Immunochina Medical Science
- lisocabtagene maraleucel: Juno Therapeutics
- YESCARTA: Gilead Sciences
- KYMRIAH: Novartis
- BREYANZI: BMS
- Cemacabtagene ansegedleucel: Allogene Therapeutics
- Rapcabtagene autoleucel (YTB323): Novartis
- Zamtocabtagene autoleucel: Miltenyi Biomedicine
- AUTO4: Autolus Therapeutics
- CD30.CAR-T: Tessa Therapeutics
Discover more about therapies set to grab major CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market share @ CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Treatment Landscape
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Drivers
- Advancements in Immunotherapy
- Efficacy in Relapsed/Refractory NHL
- FDA Approvals
- Increasing Incidence of NHL
- Ongoing Clinical Trials and Research
- Positive Patient Outcomes
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Barriers
- High Treatment Costs
- Limited Treatment Accessibility
- Complex Manufacturing Process
- Potential Side Effects
- Reimbursement Challenges
- Long-Term Efficacy and Safety Uncertainty
Scope of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Report
- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Companies: Hrain Biotechnology, Lazaros Lekakis, Beijing Immunochina Medical Science, Juno Therapeutics, Gilead Sciences, Novartis, BMS, Allogene Therapeutics, Miltenyi Biomedicine, Autolus Therapeutics, Tessa Therapeutics, and others
- Key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Therapies: Human CD19Targeted T Cells Injection, Mosunetuzumab, IM19 CAR-T Cells, lisocabtagene maraleucel, YESCARTA, KYMRIAH, BREYANZI, Cemacabtagene ansegedleucel, Rapcabtagene autoleucel (YTB323), Zamtocabtagene autoleucel, AUTO4, CD30.CAR-T, and others
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Therapeutic Assessment: CAR T-Cell Therapy for Non-Hodgkin’s lymphoma current marketed and CAR T-Cell Therapy for Non-Hodgkin’s lymphoma emerging therapies
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Dynamics: CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market drivers and CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Unmet Needs, KOL’s views, Analyst’s views, CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Access and Reimbursement
To know more about CAR T-Cell Therapy for Non-Hodgkin’s lymphoma companies working in the treatment market, visit @ CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Clinical Trials and Therapeutic Assessment
Table of Contents
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Report Introduction
- Executive Summary for CAR T-Cell Therapy for Non-Hodgkin’s lymphoma
- SWOT analysis of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Patient Share (%) Overview at a Glance
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Overview at a Glance
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Disease Background and Overview
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology and Patient Population
- Country-Specific Patient Population of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Current Treatment and Medical Practices
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Unmet Needs
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Emerging Therapies
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Outlook
- Country-Wise CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Analysis (2020–2034)
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Access and Reimbursement of Therapies
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Drivers
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Barriers
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Appendix
- CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Related Reports:
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Pipeline
"CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market. A detailed picture of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma pipeline landscape is provided, which includes the disease overview and CAR T-Cell Therapy for Non-Hodgkin’s lymphoma treatment guidelines.
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology
DelveInsight's 'CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted CAR T-Cell Therapy for Non-Hodgkin’s lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
- Medical Sterilization Equipment Market: https://www.delveinsight.com/report-store/medical-sterilization-equipment-market
- Vutrisiran Market: https://www.delveinsight.com/report-store/vutrisiran-market
- Microscopy Device Market: https://www.delveinsight.com/report-store/microscopy-device-market
- Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
- Percutaneous Arterial Closure Device Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market
- Transdermal Drug Delivery Devices: https://www.delveinsight.com/report-store/transdermal-drug-delivery-devices-market
- Infusion Pumps Market: https://www.delveinsight.com/report-store/infusion-pumps-market
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: abhishek@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
